Evidence map›Paper›PMID 31985814›Full record

ArticleBritish journal of pharmacology2020

Acetylshikonin suppressed growth of colorectal tumour tissue and cells by inhibiting the intracellular kinase, T-lymphokine-activated killer cell-originated protein kinase.

Ran Zhao, Bu Young Choi, Lixiao Wei, Mangaladoss Fredimoses, Fanxiang Yin, Xiaorong Fu, Hanyong Chen, Kangdong Liu, Joydeb Kumar Kundu, Zigang Dong and 1 more

Open access · hybridAbstract read
In one paragraph

Article in British journal of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Genome-Wide Identification ofLife (Basel, Switzerland) · 2022
    Article
  11. Article
  12. Hyperosmolality in CHO cell culture: effects on the proteome.Applied microbiology and biotechnology · 2022
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 4 countries.

Ran ZhaoDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
Bu Young ChoiDepartment of Pharmaceutical Science and Engineering, School of Convergence Bioscience and Technology, Seowon University, Chungbuk, South Korea.
Lixiao WeiChina-US (Henan) Hormel Cancer Institute, Zhengzhou, China.
Mangaladoss FredimosesChina-US (Henan) Hormel Cancer Institute, Zhengzhou, China.
Fanxiang YinDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
Xiaorong FuDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
Hanyong ChenThe Hormel Institute, University of Minnesota, Austin, Minnesota.
Kangdong LiuDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
Joydeb Kumar KunduLi Ka Shing Applied Virology Institute, University of Alberta, Edmonton, Alberta, Canada.
Zigang DongDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
Mee-Hyun LeeDepartment of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.ORCID 0000-0002-1216-0218
Zhengzhou University · CNChina-US (Henan) Hormel Cancer Institute · CNSeowon University · KRUniversity of Alberta · CAUniversity of Minnesota · US

Funding

Henan Provincial Government, ChinaKey Program of Henan Province, China 161100510300National Natural Science Foundation of China NSFC81972839 and NSFC81672767
6 · The paper itself

Abstract

background and purposeOverexpression or aberrant activation of the T-lymphokine-activated killer cell-originated protein kinase (TOPK) promotes gene expression and growth of solid tumours, implying that TOPK would be a rational target in developing novel anticancer drugs. Acetylshikonin, a diterpenoid compound isolated from Lithospermum erythrorhizon root, exerts a range of biological activities. Here we have investigated whether acetylshikonin, by acting as an inhibitor of TOPK, can attenuate the proliferation of colorectal cancer cells and the growth of patient-derived tumours, in vitro and in vivo. EXPERIMENTAL APPROACH: Targets of acetylshikonin, were identified using kinase profiling analysis, kinetic/binding assay, and computational docking analysis and knock-down techniques. Effects of acetylshikonin on colorectal cancer growth and the underlying mechanisms were evaluated in cell proliferation assays, propidium iodide and annexin-V staining analyses and western blots. Patient-derived tumour xenografts in mice (PDX) and immunohistochemistry were used to assess anti-tumour effects of acetylshikonin. KEY

resultsAcetylshikonin directly inhibited TOPK activity, interacting with the ATP-binding pocket of TOPK. Acetylshikonin suppressed cell proliferation by inducing cell cycle arrest at the G1 phase, stimulated apoptosis, and increased the expression of apoptotic biomarkers in colorectal cancer cell lines. Mechanistically, acetylshikonin diminished the phosphorylation and activation of TOPK signalling. Furthermore, acetylshikonin decreased the volume of PDX tumours and reduced the expression of TOPK signalling pathway in xenograft tumours. CONCLUSION AND IMPLICATIONS: Acetylshikonin suppressed growth of colorectal cancer cells by attenuating TOPK signalling. Targeted inhibition of TOPK by acetylshikonin might be a promising new approach to the treatment of colorectal cancer.

Indexed as

Colorectal NeoplasmsKiller Cells, Lymphokine-ActivatedAnimalsAnthraquinonesCell Line, TumorHumansMiceMitogen-Activated Protein Kinase KinasesacetylshikoninAnthraquinonesMitogen-Activated Protein Kinase Kinases

Identifiers

PMID31985814
PMCPMC7174886
OpenAlexW3000810230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.